Intelligent Therapeutics for Respiratory Diseases
"Help create a world where people with respiratory diseases can breathe easily"
We are a clinic-ready stage, biotechnology company developing new inhaled therapies for respiratory diseases, beginning with a treatment of a rare genetic disorder, Primary Ciliary Dyskinesia or PCD.
Respiratory diseases are the 3rd leading cause of death in the US and worldwide
of PCD patients experience life-threatening respiratory failure and require lung transplantation
approved treatment for PCD
Primary Ciliary Dyskinesia (PCD) is a rare and neglected disease. Patients experience chronic cough, respiratory problems, and recurrent ear and lung infections from birth onwards. Exacerbation of respiratory distress leads to frequent ER visits, hospitalization, poor quality of life for patients, and a huge economic burden. There is currently no pharmacological therapy approved specifically for the treatment of PCD. It is a critical and urgent medical need that must be addressed.
CILA therapeutics has identified and discovered several drug-candidates for the treatment of rare and common respiratory diseases including Primary Ciliary Dyskinesia, Cystic fibrosis, Bronchiectasis, Chronic Obstructive Pulmonary Diseases (COPD), COAD, Sinusitis and more.
Our drug-candidate and novel formulations are specifically designed to address acute symptoms and distress in the short term and improve the quality of life for patients. In the long term, they would prevent recurrent infections, impede the lung damage and progression of the disease. Thus preventing exacerbation, ER visit, and hospitalizations.
What is Primary Ciliary Dyskinesia (PCD)?
PCD is a rare disease caused by multiple genetic mutations involving fingerlike projections on airway cells known as "Cilia". It is estimated to affect ~1/10000 birth in the US.
Normal mucus traps pathogens and Cilia move to clear it. In PCD patients, due to genetic reasons, Cilia are dysfunctional so mucus builds up and forms plugs in airways. These plugs clog airways and initiate a vicious cycle of recurrent infection, airway damage, and permanent lung damage.
Patients experience chronic cough, respiratory problems, and recurrent ear and lung infections from birth onwards. A significant number of PCD cases experience life-threatening respiratory failure and some require lung transplantation. Exacerbation of respiratory distress leads to frequent ER visits, hospitalization, poor quality of life for patients, and a huge economic burden.
Source: Mirra et al., 2017. Frontiers in Pediatrics.
Source: NHLBI website
We have a robust early-stage pipeline with both new chemical entities (NCE) and repurposed candidates